Wednesday, February 17, 2021 9:14:18 AM
Feb. 17, 2021 8:59 AM ETArtelo Biosciences, Inc. (ARTL)By: Mamta Mayani, SA News Editor
Artelo Biosciences (NASDAQ:ARTL) rises 20% premarket following data showing potential pharmacodynamic interactions of co-administration of cannabidiol (CBD) and tetramethylpyrazine (TMP) in cell-based models of cancer.
The research focused on the components of Artelo’s CBD:TMP cocrystal program, also known as ART12.11.
The researchers found that there were synergistic and additive interactions between CBD and TMP in their abilities to prevent cancer cell growth and to kill cancer cells.
However, there was also a small reduction in the anti-migratory effect of CBD when TMP was present.
These positive initial studies warrant further in vivo preclinical research in animal tumor models.
“The study observed enhanced effects between CBD and TMP, versus either compound alone," noted Gregory Gorgas, Artelo’s President & CEO.
Full results will be reported at a future scientific conference.
Quant Rating is Bullish and Wall Street sell-siders are Very Bullish with PT of $5.00.
Recent ARTL News
- Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy • GlobeNewswire Inc. • 04/23/2024 12:30:00 PM
- Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time • GlobeNewswire Inc. • 04/22/2024 12:30:00 PM
- Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge • GlobeNewswire Inc. • 03/12/2024 01:15:00 PM
- Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy • GlobeNewswire Inc. • 01/23/2024 01:30:00 PM
- Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12 • GlobeNewswire Inc. • 01/08/2024 01:30:00 PM
- Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany • GlobeNewswire Inc. • 12/05/2023 01:30:00 PM
- Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany • GlobeNewswire Inc. • 11/30/2023 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:02:44 PM
- Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers • GlobeNewswire Inc. • 11/09/2023 02:00:00 PM
- Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023 • GlobeNewswire Inc. • 11/02/2023 12:30:00 PM
- Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia • GlobeNewswire Inc. • 10/04/2023 12:30:00 PM
- Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th • GlobeNewswire Inc. • 09/13/2023 12:30:00 PM
- Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12 • GlobeNewswire Inc. • 09/07/2023 12:00:00 PM
- Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th • GlobeNewswire Inc. • 09/06/2023 01:00:00 PM
- Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th • GlobeNewswire Inc. • 09/05/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 12:00:50 PM
- Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/10/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2023 08:57:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:34:15 PM
- Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023 • GlobeNewswire Inc. • 07/19/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/17/2023 04:15:28 AM
- Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11 • GlobeNewswire Inc. • 07/10/2023 12:30:00 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 07/07/2023 12:23:07 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM